Compare Lucid Group Inc (LCID) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs Repligen Corporation Common Stock — how do they compare? Lucid Group Inc trades at $3.28 (market cap $1.30B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 8.7× Lucid Group Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lucid Group Inc for 45 Days and Repligen Corporation Common Stock for 0 Days on average.
| LCID | RGEN | |
|---|---|---|
Market Cap | $1.30B | $11.31B |
Volume | 16,941,666 | 1,216,919 |
Sector | Consumer Cyclical | Health |
52-Week High | $21.67 | $194.57 |
52-Week Low | $3.29 | $102.87 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $4.19B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $3.36, down 2.33% amid ongoing operational challenges. The stock shows bearish technical signals with all moving averages indicating selling pressure, though oversold RSI levels suggest potential near-term bounce. Fundamentally, the company continues to burn cash with negative gross margins of -96.56% and widening losses, while recent news highlights delayed product launches and aggressive cost-cutting initiatives targeting $1.4 billion in savings.
LCID faces significant headwinds with persistent losses and cash burn threatening viability, though strategic partnerships and cost reduction efforts provide some optimism. The stock trades at deep discounts to sales and book value, but requires successful execution on new vehicle launches and substantial margin improvement to justify analyst consensus price target of $7.00, representing 109% upside from current levels.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
